RT Journal Article
SR Electronic
T1 Urological Procedures in Patients with Peritoneal Carcinomatosis of Colorectal Cancer Treated with HIPEC: Morbidity and Survival Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 295
OP 300
VO 35
IS 1
A1 HIDDE J. BRAAM
A1 THIJS R. VAN OUDHEUSDEN
A1 IGNACE H.J.T. DE HINGH
A1 SIMON W. NIENHUIJS
A1 DJAMILA BOERMA
A1 MARINUS J. WIEZER
A1 BERT VAN RAMSHORST
YR 2015
UL http://ar.iiarjournals.org/content/35/1/295.abstract
AB Aim: To investigate whether cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) is a feasible and effective option for patients with urological involvement of peritoneal carcinomatosis from colorectal cancer (CRC-PC). Patients and Methods: The characteristics of patients with CRC-PC treated with CRS+HIPEC, with or without a urological procedure, between April 2005 and June 2013 in two tertiary Centres were analyzed. Results: Thirty-eight patients (14%) out of 267 CRC-PC patients treated with CRS+HIPEC had a urological procedure during cytoreduction. The median survival was not significantly different between patients with or without a urological procedure (26.9 versus 32.1 months, p=0.29). Severe complications occurred more in patients with a urological procedure (47% versus 20%, p<0.001). In patients with a urological procedure, the most frequent complications were gastrointestinal leakage (n=9) and intra-abdominal abscess formation (n=5). Conclusion: Urological resections as a part of CRS+HIPEC in patients with peritoneal carcinomatosis of colorectal origin are feasible and effective. Severe complications are prevalent in these patients but survival is comparable to patients without involvement of the urinary system.